Look for:

Our offer for

BAUSCH HEALTH COMPANIES INC.


ISIN:
CA0717341071
WKN:
071734107

2024/04/12 22:00:00
Price
12.07 CAD
Difference -1.71% (-0.21)

General attributes

ISINCA0717341071
SymbolBHC
ExchangeToronto Stock Exchange
CurrencyCAD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)2,984 EUR
BenchmarkS&P/TSX 60 INDEX

Market data

Bid (Bid size)11.96 CAD (300)
Ask (Ask size)12.10 CAD (2,000)
Open12.15 CAD
High12.29 CAD
Low11.73 CAD
Close (prev. day)12.28 CAD
VWAP11.967448 CAD
Volume (pcs)523,572
Trading volume6,265,820.45
Number of trades3,503
Last size100

Futures and Options

Related Futures15
Related Options-

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

Date Headline Download
2024/04/03 en Global Equity Ratings PDF Download
2024/03/13 en Global Equity Ratings PDF Download
2024/02/22 en Global Equity Ratings PDF Download
2024/02/14 en Global Equity Ratings PDF Download
2024/01/23 en Global Equity Ratings PDF Download


2024/04/12 22:00:00
Price
12.07 CAD
Difference -1.71% (-0.21)

General attributes

ISINCA0717341071
SymbolBHC
ExchangeToronto Stock Exchange
CurrencyCAD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)2,984 EUR
BenchmarkS&P/TSX 60 INDEX

Market data

Bid (Bid size)11.96 CAD (300)
Ask (Ask size)12.10 CAD (2,000)
Open12.15 CAD
High12.29 CAD
Low11.73 CAD
Close (prev. day)12.28 CAD
VWAP11.967448 CAD
Volume (pcs)523,572
Trading volume6,265,820.45
Number of trades3,503
Last size100

Performance and Risk

6m1Y3Y
Perf (%)+20.94%+21.31%-67.91%
Perf (abs.)+2.09+2.12-25.54
Beta2.031.321.81
Volatility40.3752.9072.35
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)12.45 CAD (650,620)
Ø price 30 days | Ø volume 30 days (pcs.)12.99 CAD (429,066)
Ø price 100 days | Ø volume 100 days (pcs.)11.37 CAD (336,647)
Ø price 250 days | Ø volume 250 days (pcs.)10.90 CAD (376,447)
YTD High | date15.43 CAD (2024/04/03)
YTD Low | date10.10 CAD (2024/01/03)
52 Weeks High | date15.43 CAD (2024/04/03)
52 Weeks Low | date7.56 CAD (2023/05/12)

All listings for BAUSCH HEALTH COMPANIES INC.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2024/04/1222:028.23 EUR0.001
Toronto Stock Exchange2024/04/1222:0012.07 CAD6.273,503
Stuttgart2024/04/1218:518.023 EUR0.005
SIX Swiss Exchange2019/06/2817:3524.11 CHF0.001
NYSE2024/04/1222:008.76 USD45.5931,793
Munich2024/04/1208:038.381 EUR0.001
Frankfurt2024/04/1220:078.165 EUR0.003
Duesseldorf2024/04/1208:108.30 EUR0.003
Berlin2024/04/1208:038.299 EUR0.002

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=98103&ID_TYPE_IMAGE_LOGO=2

Contact Details

BAUSCH HEALTH COS. INC.
- -
2150 St. Elzéar Boulevard West - H7L 4A8 Laval
Telefon: +1-514-744-6792
Fax: +
E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.PDF Download

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board

Joseph C. PapaChairman of Managing Board
Louis YuMember of Executive Committee
Tage RamakrishnaMember of Executive Committee
Barbara PurcellMember of Executive Committee
Christina AckermannMember of Executive Committee
Dennis AsharinMember of Executive Committee
Jeff HartnessMember of Executive Committee
Joseph GordonMember of Executive Committee
Kelly WebberMember of Executive Committee
Paul S. HerendeenMember of Executive Committee
Robert SpurrMember of Executive Committee
Sam EldessoukyMember of Executive Committee
Scott HirschMember of Executive Committee
Thomas AppioMember of Executive Committee

Board of directors

John PaulsonChairman of Supervisory Board
Amy WechslerMember of Supervisory Board
Richard MulliganMember of Supervisory Board
Brett IcahnMember of Supervisory Board
Robert PowerMember of Supervisory Board
Russel RobertsonMember of Supervisory Board
Sarah KavanaghMember of Supervisory Board
Steven MillerMember of Supervisory Board
Thomas RossMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer